Introduction
Many colorectal cancers (CRCs) develop in individuals who are genetically susceptible but are not carriers of germline mismatch repair or APC (Adenomatous polyposis coli) gene mutations (1) (2) (3) . Much of the heritable risk of CRC is now thought to be caused by the coinheritance of multiple low-risk variants (1) (2) (3) . Single-nucleotide polymorphisms (SNPs) localizing to 16 independent chromosome regions [1q41 (4), 3q26.2 (4), 8q23.3 (5), 8q24.21 (6, 7) , 10p14 (5), 11q23.1 (8), 12q13.13 (4), 14q22.2 (9,10), 15q13.3 (11), 16q22.1 (10), 18q21.1 (12), 19q13.11 (10) , 20p12.3 (9,10) and 20q13.33 (4) ] have been shown to influence the risk of developing CRC.
An important long-term outcome of genome-wide association studies and follow-up studies is the knowledge gained about the basis of CRC carcinogenesis. To date, most analyses of the relationship between SNP genotype and CRC phenotype have not taken into account the fact that the disease is heterogeneous. Colorectal cancer develops along at least two biologically distinct pathways characterized by different genetic abnormalities. The chromosome instability pathway is typified by chromosomal abnormalities resulting in loss of heterozygosity and tumour suppressor gene inactivation, whereas cancers exhibiting microsatellite instability (MSI) have defective DNA mismatch repair. Sporadic MSI-high tumours are related to a group of CIMPþ tumours characterized by methylation of multiple CpG islands (13) . Tumours with MSI-H and CIMPþ are typically chromosomally stable (i.e. near diploid). There are also data supporting colon cancer and rectal cancer being different diseases (14) (15) (16) ).
Here we have aimed to determine whether if any of the 16 CRC susceptibility variants differentially impact on CRC phenotype to confirm them as distinct and aetiologically different risk factors in colorectal carcinogenesis. To this end, we have analysed a large population-based series of UK CRC cases.
Materials and methods

Study subjects
Colorectal cancer cases, aged ,80 years at diagnosis, were ascertained through the National Study of Colorectal Cancer Genetics, an ongoing populationbased study in the UK (17) of histology proven CRC within 5 years of diagnosis, with no exclusion for known genetic susceptibility. The current study is based on 3146 cases ascertained between March 2003 and April 2007. To estimate risk of CRC associated with variants, we performed a case-control analysis. Controls were the spouses of cancer cases (n 5 6051) and were ascertained between June 1999 and April 2007 through the National Study of Colorectal Cancer Genetics (n 5 1933); the Genetic Lung Cancer Predisposition Study (n 5 1628) (18) ; the Colorectal Adenoma Gene-Environment Interactions Study (n 5 707) (19) and the Royal Marsden Hospital National Health Services Trust family history DNA database (n 5 1783). None of the controls had a personal history of malignancy at ascertainment. Demographic data were collected through a self-administered questionnaire based on the National Study of Colorectal Cancer Genetics format but did not seek information on a family history of cancer. There was an average age at diagnosis of 58.9 and 59.0 for cases and controls, respectively. All cases and controls were British residents with self-reported European ethnicity and the geographical distribution of cases and controls was similar. Informed written consent was obtained from all subjects, and the study was carried out with ethical review board approval Genotyping DNA was extracted from ethylenediaminetetraacetic acid-venous blood samples by using conventional methodologies and PicoGreen quantified (Invitrogen Corp, Carlsbad, CA). We analysed 16 SNPs, the 16 chromosomal regions reported to be robustly associated with CRC risk: rs6691170 (1q41) (4), rs10936599 (3q26.2) (4), rs16892766 (8q23.3) (4), rs6983267 (8q24.21) (6,7), rs10795668 (10p14) (5), rs3802842 (11q23.1) (8), 12q13.13 (rs11169552) (4), rs4444235 and rs1957636(14q22.2) (10), rs4779584 (15q13.3) (11), rs9929218 (16q22.1) (10), rs4939827 (18q21.1) (12), rs10411210 (19q13.11) (10), rs961253 and rs4813802 (20p12.3) (10) and rs4925386 (20q13.33) (4). SNP genotyping was performed by KASPar allele-specific polymerase chain reaction (KBioscience, Hertsfordshire, UK; primer sequences and conditions are available on request). To monitor quality control, a set of 136 duplicate samples were included in assays; genotype concordance was .99.9%. To confirm genotypes, we sequenced 192 samples chosen randomly from cases and controls; concordance between genotypes was 100%.
Tumour MSI status in CRCs was determined as described previously (17) using the mononucleotide microsatellite loci BAT25 and BAT26, which are highly sensitive MSI markers. Briefly, 10 mm sections were cut from formalinfixed paraffin-embedded CRC tumours, lightly stained with toluidine blue and regions containing at least 60% tumour microdissected. Tumour DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Crawley, UK) according to the manufacturer's instructions and genotyped for the BAT25 and BAT26 loci. Samples showing more than or equal to five novel alleles, when compared with normal DNA, at either or both markers were assigned as MSI-H (corresponding to MSI-high) (20) . Tumours showing only small DNA shifts at these markers rerun directly adjacent to a normal DNA control to assign MSI status. , and MSI status were tested by case-only analysis using logistic regression, with and without adjusting for age and sex. The CRC risk associated with SNPs was calculated by odds ratios using unconditional logistic regression. A P value (two sided) 0.05 was considered statistically 
Statistical analysis
Results
In total, 1819of the 3146 patients were male (57.8%). The average age of CRC diagnosis in patients was 58.9 years, with a median of 60.0 years and a range of 17-80 years. With regard to tumour pathology, the proportion of patients reported with stage A, B, C and D disease was 9.9% (n 5 310), 33.8% (n 5 1062), 49.8% (n 5 1567) and 0.8% (n 5 24), respectively. A small percentage (5.8%) had unknown stage status; 12.5% (n 5 358) of tumours were graded as poorly differentiated and 87.5% (n 5 2500) as moderate/well differentiated; 2062 (65.5%) of the patients had colonic disease (ICD9-153; 9.3% in appendix, 14.6% in caecum, 9.3% in the ascending colon, 2.0% in the hepatic flexure, 5.4% in the transverse colon, 2.2% in the splenic flexure, 4.0% in the descending colon, 27.7% in the sigmoid colon); 1084 (34.5%) had rectal disease (ICD9-154; 6.6% in the rectosigmoid junction, 27.8% in the rectum) and in 0.4% the tumour site was unspecified. Genotyping success for SNPs was between 97and 99%. The gene variants on 8q24.21, 10p14, 16q22.1, 18q21.1 and 19q13.11 have been published to have a protective effect (5) (6) (7) (8) 10, 12) , meaning that the most common variant (the wild-type allele) constitutes the risk allele. For consistency, we will address the results associated with the risk allele, regardless of whether this was the common variant or not. For all CRC, each of the 14 SNPs showed an association with CRC risk, with only the 14q22.2 association annotated by rs1957636 not attaining statistical significance (Table I) .
Case-only analysis was employed to examine for genotype-phenotype correlations. None of the 16 SNPs showed a statistically significant association with either tumour stage or grade (Supplementary Tables  1 and 2 , available at Carcinogenesis online). Table II shows the relationship between SNP genotype and tumour site. Five SNPs showed a difference in genotype frequencies between patients with colonic and rectal disease (rs6691170, rs4939827, rs3802842, rs961253 and rs4813802). In addition, there was evidence for a borderline association between rs4779584 genotype and tumour site. Table II also shows the relationship between SNP genotype and tumour site, stratified by MSI status. Seven SNPs showed differences in genotype frequencies between patients with colonic and rectal disease. Genotype frequencies for five SNPs were significantly different between patients with microsatellite stable (MSS) colonic tumours and MSS rectal tumours-rs6691170, rs3802842, rs4779584, rs4939827, rs961253, and rs4813802 (Table II) . For MSI cancers, two SNPs, rs4444235 and rs4925386, showed differences in genotype frequencies between colonic and rectal cancers (Table II) . These genotype-phenotype relationships are reflected in the CRC risks shown by rs6691170 and rs3802842 for MSS rectal cancer and among rs4779584, rs961253 and rs4813802 for MSS colon cancer (Table III) . Similarly the differential risks associated with rs4444235 and rs4925386 for MSI colon and rectal cancers. Although not formally statistically significant, the association between rs4939827 with CRC risk was stronger for MSS rectal than MSS colonic disease.
Discussion
As well as providing vindication of a model of CRC susceptibility in which multiple low-risk alleles contribute to disease susceptibility, the 16 risk loci identified so far have already provided important novel insights into CRC biology, with several suggesting the involvement of components of the transforming growth factor beta superfamily signalling pathway as an aetiological basis for CRC development (21) . To date tumour heterogeneity has been largely ignored in analyses. It seems highly likely a priori that the impact of genetic variation at these loci will not be universally generic and that some of the risk variants will impact preferentially on subtypes. The strongest evidence that constitutional genotype influences CRC phenotype is provided by tumours originating in the context of familial adenomatous polyposis and hereditary non-polyposis colorectal cancer that impact on different pathways-with mutations in the APC and the mismatch repair genes deregulating the Wnt and transforming growth factor beta receptor 1-signalling pathways, respectively.
In addition to the distinction between MSI and MSS cancers, there is increasing evidence that colon cancer and rectal cancer are different entities. Aetiologically, factors such as race, gender, age, and other epidemiological risk factors have been shown to differentially affect CRC risk at the two sites (22) . Intriguingly a family history of CRC appears to affect the risk of colon cancer more than rectal cancer, consistent with a stronger genetic basis to cancer at this site. MSI is rare in rectal carcinoma (23), whereas the incidence of chromosome instability is high (14, 24, 25) . Mutations are significantly higher in rectal than colonic cancer (14) and rectal cancers display more nuclear b-catenin than colon cancers (26) . Additionally, rectal cancers are less K-ras-dependent and the APC gene-restricting pattern is predominant (14) . Collectively, these data favour dysregulation of the APC/b-catenin pathway being a main feature of rectal cancer in contrast with colonic cancer. Thus, CRC risk variants are likely to impact differentially dependent on tumour site. 
Colorectal cancer susceptibility loci and tumour phenotype
Here we have validated the previously reported association between variation at 11q23.1 (rs3802842) and 18q21.1 (rs4939827) and risk of developing rectal cancer (8) . In addition, we have provided evidence that 1q41 genotype (rs6691170) is also a marker for risk of rectal cancer. It is currently difficult to hypothesize how these correlations might be interpreted biologically as the functional basis of these associations that do not annotate genes has yet to be elucidated.
In addition to these correlations, our study has provided evidence that the SNPs annotating the BMP2, BMP4, GREM1 and LAMA5 genes-rs477984, rs961253, rs4813802, rs444235 and rs4925386, respectively-preferentially impact on colonic cancer risk. Given that these genes encode components of the extended transforming growth factor beta-signalling pathway, this is entirely plausible given the pivotal role that the dysregulation in this pathway has in colonic disease. Although the biological basis of genetic variation at these loci has yet to be fully understood, we have shown that the functional basis of the 14q22.2 is mediated through cis-acting allele-specific down-regulation of BMP4 (27) .
Similarly to other reports, we found no evidence that rs6983267 at 8q24.21 is associated with sex, age at diagnosis, tumour site or stage (28) (29) (30) . However, we did not replicate the previously published association of the variant with MSI status (30) or tumour site and stage (31) . We also found no evidence that the 10p14 locus (rs10795668) is associated with poorly differentiated tumours as previously purported (32) .
Since we have not sought to adjust for multiple comparisons, it cannot therefore be ruled out that some of our results may be false positives. Hence our results are preliminary, and additional studies are required to confirm study findings. Colorectal cancer is complex disease; hence, it is expected that genetic variation at multiple loci will impact collectively to influence risk and phenotype effects. Our findings are consistent with the pathogenic variants in these loci acting in distinct morphogenetic pathways. Potentially such knowledge has future clinical application in prevention and therapeutic strategies.
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